Combination Chemotherapy and Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma

This study is ongoing, but not currently recruiting new participants.

This phase I/II trial studies the side effects and best dose of lenalidomide when given together with combination chemotherapy and to see how well they work in treating patients with newly diagnosed stage II-IV peripheral T-cell non-Hodgkin's lymphoma. Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and etoposide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Lenalidomide may stop the growth of peripheral T-cell non-Hodgkin's lymphoma by blocking the growth of new blood vessels necessary for cancer growth. Giving combination chemotherapy with lenalidomide may be a better treatment for peripheral T-cell non-Hodgkin's lymphoma.

Study Type:  Interventional

Study Design:  

Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Official Title:  A Phase I/II Trial of CHOEP Chemotherapy Plus Lenalidomide as Front Line Therapy for Patients With Stage II, III and IV Peripheral T-Cell Non-Hodgkin Lymphoma

Conditions:  

Anaplastic Large Cell Lymphoma, ALK-Negative
Anaplastic Large Cell Lymphoma, ALK-Positive
Hepatosplenic T-Cell Lymphoma
Peripheral T-Cell Lymphoma, Not Otherwise Specified
Stage II Angioimmunoblastic T-cell Lymphoma
Stage II Enteropathy-Associated T-Cell Lymphoma
Stage III Angioimmunoblastic T-cell Lymphoma
Stage III Enteropathy-Associated T-Cell Lymphoma
Stage IV Angioimmunoblastic T-cell Lymphoma
Stage IV Enteropathy-Associated T-Cell Lymphoma

Interventions:  

Drug: Cyclophosphamide
Drug: Doxorubicin Hydrochloride
Drug: Vincristine Sulfate
Drug: Etoposide
Drug: Prednisone
Drug: Lenalidomide
Procedure: Peripheral Blood Stem Cell Transplantation
Procedure: Autologous Hematopoietic Stem Cell Transplantation
Other: Laboratory Biomarker Analysis

Phase:  Phase 1, Phase 2

External Link:  https://clinicaltrials.gov/ct2/show/NCT02561273